| 1.81 Data as of 1:17pm ET | +0.035 / +1.97%Today’s Change | 1.65 Today|||52-Week Range 6.24 | -5.73% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $110.4M |
Company Description
Oncothyreon, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. Its product pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications, including Stimuvax, PX-866, ONT-701 and ONT-10. The company's cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Oncothyreon was founded in 1985 and is headquartered in Seattle, WA.
Employees

Shareholders
| Other institutional | 38.30% |
| Individual stakeholders | 19.05% |
| Mutual fund holders | 14.10% |
Top Executives
| Robert L. Kirkman, MD | President, Chief Executive Officer & Director |
| Gary Christianson | Chief Operating Officer |
| Julia Marie Eastland, MBA | CFO, Secretary & VP-Corporate Development |
| Diana Hausman, PhD | Chief Medical Officer & VP-Clinical Development |
| Scott Robert Peterson, PhD | Chief Scientific Officer |